JPMorgan upgraded Afya (AFYA) to Overweight from Neutral with a price target of $24.50, up from $23.50. The company’s focus on medical education ?provides superior consistency and visibility,” the analyst tells investors in a research note. The firm says Afya is one of the most consistent players in the Brazilian education industry, with high visibility and never missing guidance. It views the stock as a “solid pick for the risk-averse.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AFYA: